Distribution of a somatostatin analog after continuous intraventricular administration

Decreased somatostatin in the brains of patients with Alzheimer's disease has led to an investigation of the efficacy of neurotransmitter replacement therapy. The distribution of a somatostatin analog, octreotide, was determined after 2 to 6 days of continuous intraventricular infusion at 40 mi...

Full description

Saved in:
Bibliographic Details
Published inNeurosurgery Vol. 24; no. 5; p. 744
Main Authors Kroin, J S, O'Dorisio, T M, Penn, R D, Haklin, M F, Howe, B A
Format Journal Article
LanguageEnglish
Published United States 01.05.1989
Subjects
Animals
Brain - metabolism
Dogs
Injections, Intraventricular
Male
Octreotide - administration & dosage
Octreotide - pharmacokinetics
Tissue Distribution
Online AccessGet more information

Cover

More Information
Summary:Decreased somatostatin in the brains of patients with Alzheimer's disease has led to an investigation of the efficacy of neurotransmitter replacement therapy. The distribution of a somatostatin analog, octreotide, was determined after 2 to 6 days of continuous intraventricular infusion at 40 micrograms/h in dogs. The tissue concentration was greater than 100 ng/g wet weight in all parts of the brain, which is greater than the normal concentration of native somatostatin. There was no reduction in native somatostatin production because of the infusion of the analog. The cerebrospinal fluid octreotide concentration was 1000 times greater than the plasma concentration. The results demonstrate that neurotransmitter replacement for somatostatin can be achieved by chronic intraventricular infusion of a metabolically stable analog.
ISSN:0148-396X
DOI:10.1227/00006123-198905000-00014